Evorpacept Development Plan
Combination Agent
AND ADCS
Gastroesophageal Junction Cancer)
GC
Gastric/
Gastroesophageal Junction Cancer
AND ADCS
Urothelial Cancer
AND ADCS
Breast Cancer
AND ADCS
Breast Cancer
AND ADCS
MM
Multiple Myeloma
INHIBITORS
Squamous Cell,
Carcinoma)
HNSCC
Head and Neck,
Squamous Cell,
Carcinoma
INHIBITORS
Squamous Cell,
Carcinoma)
HNSCC
Head and Neck,
Squamous Cell,
Carcinoma
ALX Oncology retains world-wide rights to evorpacept
1. ALX Oncology conducts and sponsors ASPEN-06, Lilly supplies Cyramza
2. Jazz Pharmaceuticals conducts and sponsors clinical trial, ALX Oncology supplies evorpacept
3. Quantum Leap Healthcare Collaborative conducts and sponsors clinical trial, ALX Oncology supplies evorpacept
4. Sanofi conducts and sponsors clinical trial, ALX Oncology supplies evorpacept
5. ALX Oncology conducts and sponsors ASPEN-03 and ASPEN-04, Merck supplies Keytruda
Clinical Trials
ALX Oncology Sponsored Trials
- ALX148 in Combination with Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
- ALX148 in Combination with Pembrolizumab and Chemotherapy in Patients with Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
- A Study of Evorpacept (ALX148) in Patients with Advanced HER2+ Gastric Cancer (ASPEN-06)
- A Study of Evorpacept (ALX148) with Enfortumab Vedotin for Subjects with Urothelial Carcinoma (ASPEN-07)
Collaboration Partner Sponsored Trials
Investigator Sponsored Trials
- ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
- Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer
- Neoadjuvant Immunoradiotherapy with Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)
Expanded Access Policy
ALX Oncology is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. The goal of our current clinical study program is to enroll patients and obtain clinical data on evorpacept that is required by the US Food and Drug Administration (FDA) and other regulatory authorities for review and approval of marketing applications for this investigational agent.
We believe that focusing on clinical studies is the most appropriate way to achieve this goal; therefore, we do not currently offer access to evorpacept outside of clinical studies and, at this time, we have no Expanded Access Program (sometimes referred to as “compassionate use” or “pre-approval access”).
If you have additional questions regarding this policy, please speak with your health care provider or contact: info@alxoncology.com